Atovaquone-proguanil remains a potential stopgap therapy for multidrug-resistant Plasmodium falciparum in areas along the Thai-cambodian border

Antimicrobial Agents and Chemotherapy

Volumn 60, Issue 3, 2016, Pages 1896-1898

  Saunders, David L ^a   Chaorattanakawee, Suwanna ^a   Gosi, Panita ^a   Lanteri, Charlotte ^a   Somethy, Sok ^d   Kuntawunginn, Worachet ^a   Ittiverakul, Mali ^a   Chann, Soklyda ^c   Gregory, Carrie ^a   Chuor, Char Meng ^b   Prom, Satharath ^d   Spring, Michele D ^a   Lon, Chanthap ^c  

^a ARMED FORCES RESEARCH INSTITUTE OF MEDICAL SCIENCES   (Thailand)

^b National Center for Parasitology Entomology and Malaria Control   (Cambodia)

^c USAMC AFRIMS   (Cambodia)

^d Royal Cambodian Armed Forces   (Cambodia)

Author keywords

[No Author keywords available]

Indexed keywords

ARTEMISININ; ARTESUNATE; ATOVAQUONE PLUS PROGUANIL; CHLOROQUINE; CYTOCHROME B; DIHYDROARTEMISININ; DIHYDROARTEMISININ PLUS PIPERAQUINE; MEFLOQUINE; PIPERAQUINE; QUININE; ANTIMALARIAL AGENT; ARTEMISININ DERIVATIVE; ATOVAQUONE; ATOVAQUONE, PROGUANIL DRUG COMBINATION; DRUG COMBINATION; PROGUANIL; PROTOZOAL DNA; QUINOLINE DERIVATIVE;

ARTICLE; CAMBODIA; CLONE; CONTROLLED STUDY; DOSE RESPONSE; DRUG EFFICACY; DRUG TREATMENT FAILURE; EX VIVO STUDY; GENETIC POLYMORPHISM; GENETIC RESISTANCE; GENOTYPE; HUMAN; IC50; IN VITRO STUDY; MAJOR CLINICAL STUDY; MALARIA FALCIPARUM; MULTIDRUG RESISTANCE; PLASMODIUM FALCIPARUM; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; SINGLE NUCLEOTIDE POLYMORPHISM; THAILAND; DNA SEQUENCE; DRUG COMBINATION; DRUG EFFECTS; DRUG SENSITIVITY; GENETICS; ISOLATION AND PURIFICATION; MALARIA, FALCIPARUM; NUCLEOTIDE SEQUENCE; PARASITOLOGY;

ANTIMALARIALS; ARTEMISININS; ATOVAQUONE; BASE SEQUENCE; CAMBODIA; DNA, PROTOZOAN; DRUG COMBINATIONS; DRUG RESISTANCE, MULTIPLE; HUMANS; MALARIA, FALCIPARUM; PARASITIC SENSITIVITY TESTS; PLASMODIUM FALCIPARUM; PROGUANIL; QUINOLINES; SEQUENCE ANALYSIS, DNA; THAILAND;

EID: 84960332651     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.02302-15     Document Type: Article

References (21)

1. Noedl H, Se Y, Schaecher K, Smith BL, Socheat D, Fukuda MM, Artemisinin Resistance in Cambodia 1 (ARC1) Study Consortium. 2008. Evidence of artemisinin-resistant malaria in western Cambodia. N Engl J Med 359:2619-2620. http://dx.doi.org/10.1056/NEJMc0805011.
2. Lon C, Manning JE, Vanachayangkul P, So M, Sea D, Se Y, Gosi P, Lanteri C, Chaorattanakawee S, Sriwichai S, Chann S, Kuntawunginn W, Buathong N, Nou S, Walsh DS, Tyner SD, Juliano JJ, Lin J, Spring M, Bethell D, Kaewkungwal J, Tang D, Chuor CM, Satharath P, Saunders D. 2014. Efficacy of two versus three-day regimens of dihydroartemisinin-piperaquine for uncomplicated malaria in military personnel in northern Cambodia: an open-label randomized trial. PLoS One 9:e93138. http://dx.doi.org/10.1371/journal.pone.0093138.
3. Saunders DL, Vanachayangkul P, Lon C, U.S. Army Military Malaria Research Program, National Center for Parasitology Entomology, and Malaria Control (CNM), Royal Cambodian Armed Forces. 2014. Dihydroartemisinin-piperaquine failure in Cambodia. N Engl J Med 371:484-485. http://dx.doi.org/10.1056/NEJMc1403007.
4. World Health Organization. 2012. National treatment guidelines for malaria in Cambodia. World Health Organization, Geneva, Switzerland. http://whothailand.healthrepository.org/bitstream/123456789/1442/1/NTG%20in%20English-Final.pdf.
5. Boggild AK, Parise ME, Lewis LS, Kain KC. 2007. Atovaquoneproguanil: report from the CDC expert meeting on malaria chemoprophylaxis (II). Am J Trop Med Hyg 76:208-223.
6. Fry M, Pudney M. 1992. Site of action of the antimalarial hydroxynaphthoquinone, 2-[trans-4-(4=-chlorophenyl) cyclohexyl]-3-hydroxy-1,4-naphthoquinone (566C80). Biochem Pharmacol 43:1545-1553. http://dx.doi.org/10.1016/0006-2952(92)90213-3.
7. Siregar JE, Syafruddin D, Matsuoka H, Kita K, Marzuki S. 2008. Mutation underlying resistance of Plasmodium berghei to atovaquone in the quinone binding domain 2 (Qo(2)) of the cytochrome b gene. Parasitol Int 57:229-232. http://dx.doi.org/10.1016/j.parint.2007.12.002.
8. Syafruddin D, Siregar JE, Marzuki S. 1999. Mutations in the cytochrome b gene of Plasmodium berghei conferring resistance to atovaquone. Mol Biochem Parasitol 104:185-194. http://dx.doi.org/10.1016/S0166-6851(99)00148-6.
9. Siregar JE, Kurisu G, Kobayashi T, Matsuzaki M, Sakamoto K, Mi-ichi F, Watanabe Y, Hirai M, Matsuoka H, Syafruddin D, Marzuki S, Kita K. 2015. Direct evidence for the atovaquone action on the Plasmodium cytochrome bc1 complex. Parasitol Int 64:295-300. http://dx.doi.org/10.1016/j.parint.2014.09.011.
10. Schwobel B, Alifrangis M, Salanti A, Jelinek T. 2003. Different mutation patterns of atovaquone resistance to Plasmodium falciparum in vitro and in vivo: rapid detection of codon 268 polymorphisms in the cytochrome b as potential in vivo resistance marker. Malar J 2:5. http://dx.doi.org/10.1186/1475-2875-2-5.
11. Sutherland CJ, Laundy M, Price N, Burke M, Fivelman QL, Pasvol G, Klein JL, Chiodini PL. 2008. Mutations in the Plasmodium falciparum cytochrome b gene are associated with delayed parasite recrudescence in malaria patients treated with atovaquone-proguanil. Malar J 7:240. http://dx.doi.org/10.1186/1475-2875-7-240.
12. Kamau E, Alemayehu S, Feghali KC, Saunders D, Ockenhouse CF. 2013. Multiplex qPCR for detection and absolute quantification of malaria. PLoS One 8:e71539. http://dx.doi.org/10.1371/journal.pone.0071539.
13. Chaorattanakawee S, Tyner SD, Lon C, Yingyuen K, Ruttvisutinunt W, Sundrakes S, Sai-gnam P, Johnson JD, Walsh DS, Saunders DL, Lanteri CA. 2013. Direct comparison of the histidine-rich protein-2 enzymelinked immunosorbent assay (HRP-2 ELISA) and malaria SYBR green I fluorescence (MSF) drug sensitivity tests in Plasmodium falciparum reference clones and fresh ex vivo field isolates from Cambodia. Malar J 12:239. http://dx.doi.org/10.1186/1475-2875-12-239.
14. Tyner SD, Lon C, Se Y, Bethell D, Socheat D, Noedl H, Sea D, Satimai W, Schaecher K, Rutvisuttinunt W, Fukuda MM, Chaorattanakawee S, Yingyuen K, Sundrakes S, Chaichana P, Saingam P, Buathong N, Sriwichai S, Chann S, Timmermans A, Saunders DL, Walsh DS. 2012. Ex vivo drug sensitivity profiles of Plasmodium falciparum field isolates from Cambodia and Thailand, 2005 to 2010, determined by a histidinerich protein-2 assay. Malar J 11:198. http://dx.doi.org/10.1186/1475-2875-11-198.
15. Chaorattanakawee S, Saunders DL, Sea D, Chanarat N, Yingyuen K, Sundrakes S, Saingam P, Buathong N, Sriwichai S, Chann S, Se Y, Yom Y, Heng TK, Kong N, Kuntawunginn W, Tangthongchaiwiriya K, Jacob C, Takala-Harrison S, Plowe C, Lin JT, Chuor CM, Prom S, Tyner SD, Gosi P, Teja-Isavadharm P, Lon C, Lanteri CA. 2015. Ex vivo drug susceptibility testing and molecular profiling of clinical Plasmodium falciparum isolates from Cambodia from 2008 to 2013 suggest emerging piperaquine resistance. Antimicrob Agents Chemother 59:4631-4643. http://dx.doi.org/10.1128/AAC.00366-15.
16. Rutvisuttinunt W, Chaorattanakawee S, Tyner SD, Teja-Isavadharm P, Se Y, Yingyuen K, Chaichana P, Bethell D, Walsh DS, Lon C, Fukuda M, Socheat D, Noedl H, Schaecher K, Saunders DL. 2012. Optimizing the HRP-2 in vitro malaria drug susceptibility assay using a reference clone to improve comparisons of Plasmodium falciparum field isolates. Malar J 11:325. http://dx.doi.org/10.1186/1475-2875-11-325.
17. Musset L, Pradines B, Parzy D, Durand R, Bigot P, Le Bras J. 2006. Apparent absence of atovaquone/proguanil resistance in 477 Plasmodium falciparum isolates from untreated French travellers. J Antimicrob Chemother 57:110-115.
18. Gan LS, Loh JP. 2010. Rapid identification of chloroquine and atovaquone drug resistance in Plasmodium falciparum using high-resolution melt polymerase chain reaction. Malar J 9:134. http://dx.doi.org/10.1186/1475-2875-9-134.
19. Sanger F, Nicklen S, Coulson AR. 1977. DNA sequencing with chainterminating inhibitors. Proc Natl Acad Sci U S A 74:5463-5467. http://dx.doi.org/10.1073/pnas.74.12.5463.
20. Nakato H, Vivancos R, Hunter PR. 2007. A systematic review and metaanalysis of the effectiveness and safety of atovaquone proguanil (Malarone) for chemoprophylaxis against malaria. J Antimicrob Chemother 60:929-936. http://dx.doi.org/10.1093/jac/dkm337.
21. Maude RJ, Nguon C, Dondorp AM, White LJ, White NJ. 2014. The diminishing returns of atovaquone-proguanil for elimination of Plasmodium falciparum malaria: modelling mass drug administration and treatment. Malar J 13:380. http://dx.doi.org/10.1186/1475-2875-13-380.